Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

7 notable pulmonary fibrosis research efforts 

By Brian Buntz | February 1, 2021

lungs

Image courtesy of Pixabay

Idiopathic pulmonary fibrosis (IPF) is frequently a debilitating disease associated with significant morbidity and mortality. Although a rare disease, its incidence has increased in recent decades, and it leads to more deaths than some cancers. 

The treatment landscape for the condition changed in 2014 when FDA approved the first drugs indicated for IPF, nintedanib from Boehringer Ingelheim and pirfenidone from Roche (OTCMKTS:RHHBY). 

[Related: The pulmonary fibrosis treatment landscape: An interview with an expert]

Research on pulmonary fibrosis has increased in recent years. 

Here’s a summary of notable IPF research: 

  • Boehringer Ingelheim has an international study investigating a phosphodiesterase 4b (BI 1015550) inhibitor in patients with idiopathic pulmonary fibrosis. Researchers have found that the drug has anti-fibrotic effects in animal models and lung fibrosis cellular models. The compound is currently the subject of Phase 2 trials enrolling patients in 25 countries. Phosphodiesterase-4 inhibitors themselves are not new to drug companies. Schering, for instance, developed a selective phosphodiesterase-4 inhibitor known as Rolipram as a possible antidepressant in the 1990s. The molecule has since become a template for other drug discovery and development efforts. Research on Rolipram also continues to be active. 
  • Bellerophon Therapeutics (NSDQ:BLPH) announced in late 2020 that it had enrolled the first patient in its Phase 3 REBUILD trial investigating a pulsed inhaled nitric oxide therapy known as INOpulse as a possible fibrotic interstitial lung disease treatment. Prior clinical data showed the therapy had benefits for pulmonary fibrosis patients engaged in moderate-to-vigorous physical activity. 
  • Genentech, which belongs to Roche (OTCMKTS:RHHBY), has a Phase 3 STARSCAPE trial underway investigating the use of a recombinant human pentraxin-2 protein (PRM-151) in patients with idiopathic pulmonary fibrosis (IPF). Previous clinical research has correlated low serum levels of the pentraxin-2 protein with disease severity in individuals with idiopathic pulmonary fibrosis. 
  • Bristol Myers Squibb (NYSE:BMY) has two Phase 2 trials underway related to pulmonary fibrosis related to the c-Jun N-terminal kinase inhibitor CC-90001 the lysophosphatidic acid receptor 1 antagonist BMS-986278.
  • Galecto (NSDQ:GLTO) is working on small-molecule fibrosis inhibitors such as GB0139, a galectin-3 inhibitor delivered by dry powder inhalation. The company has launched preclinical testing of inhaled galectin-3, a protein that plays a role in fibrosis in several organs. Evidence suggests that GB0139 inhibits fibrosis by targeting macrophages, fibroblasts and epithelial cells. GB0139 has received Orphan Drug Designation from FDA and the European Medicines Agency. 
  • Veracyte (NSDQ:VCYT) has developed the Envisia Genomic Classifier, a genomic test intended to improve the diagnosis of idiopathic pulmonary fibrosis when used in concert with high-resolution computed tomography. The company’s BRAVE study found that the technology had a specificity rate of 91% with less than 10% false positives. 
  • FibroGen (NSDQ:FGEN) has a Phase 3 study known as ZEPHYRUS that is investigating its novel drug for IPF, pamrevlumab. Pamrevlumab is a fully humanized monoclonal antibody that targets activity of connective tissue growth factor, which is a mediator for tissue remodeling and fibrosis. PRAISE, a previous randomized, double-blind Phase 2b trial, showed significantly reduced forced vital capacity (FVC) decline. Adverse effects from pamrevlumab were similar in placebo and treatment arms of the study.

 

Comments

  1. Jerry Hinkey says

    February 12, 2021 at 2:48 am

    I would be interested in any information trails regarding IPF.

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Ivermectin not supported for mild COVID-19, study says
Emulate Bio
Organ-chips could streamline drug development, but hurdles remain
Novavax
Novavax stock dips 14% on the heels of Q4 announcement
Amgen/AstraZeneca
After flunking one study, Amgen’s tezepelumab shows promise for asthma

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards